Calcium and Vitamin D Supplements Do Not Reduce Hip Fractures

Save

Recent JAMA study shows metanalysis of 33 clinical trials and 51,145 participants, showed that calcium, vitamin D, or both affords no decreased risk of hip fractures compared with placebo or no treatment and therefore questions their routine widespread use in the elderly.. 

The RheumNow Week in Review - 5 January 2018

Save

Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  

Sorting Out the Complexities of Autoimmunity with Immune Checkpoint Inhibitor Therapy

Save

An editorial and systematic review of complications seen when checkpoint inhibitor (CPI) therapies are given to patients with immune mediated inflammatory disorders (IMIDs) and cancer shows that nearly 75% manifest autoimmune and inflammatory immune-related adverse events (irAEs).

Community Screening for Fracture Risk in Older Women is Effective and Feasible

Save

A UK Study published in Lancet shows that community-based screening programme for fracture risk in older women is feasible, and may reduce hip fractures. 

Despite Increasing Metric Use, They Are Not Widespread in Rheumatoid Care

Save

The Journal of Rheumatology has published a nationwide survey of US rheumatologists and shown that despite trends for increasing metric assessments, nearly half of rheumatoid arthritis (RA) patients are not routinely assessed with a disease activity metric and the evidence they

Bone Marrow Edema May be Found in Normals, Athletes and Military Recruits

Save

Rheumatology has published a study demonstrating that bone marrow edema as measured by magnetic resonance imaging (MRI) may be found in healthy people, but that such changes do not change with intense physical activity.

MEASURE 3 Study - Anti-IL17 Benefits Persist in Spine Disease

Save

Patients with ankylosing spondylitis (AS) have shown rapid and sustained responses to secukinumab (Cosentyx) in a third phase III trial that includes a higher dose of this anti-interleukin-17A monoclonal antibody, researchers reported.

New BSR 2017 Gout Guidelines (Best of 2017)

Save

The British Society for Rheumatology/British Health Professionals in Rheumatology first published a guideline for the management of gout in 2007. They have just updated and published their new guideline, largely because of new therapies, an increasing incidence of gout, low penetrance of urate lowering therapies, and the inability to achieve a target serum uric acid level.

Therapeutic Update: 5 Questions on FDA Hearing for Tofacitinib in PsA (Best of 2017)

Save

In this Therapeutic Update, Drs. Mease, Gibofsky and Cush answer five questions regarding the August 3rd FDA Arthritis Advisory Committee meeting that reviewed the potential approval of tofacitinib (Xeljanz) in patients with active psoriatic arthritis. The panel was nearly unanimous (10-1) in favor of the efficacy and safety profile of of tofacitinib, and similarly voted 10-1 to approve this drug for use in PsA. Final decisions on these recommendations from the AAC panel will be made at a later date by the FDA. 

The RheumNow Week in Review - 22 December 2017

Save

Dr. Jack Cush reviews highlights and news from the past week on RheumNow.com. 

Allopurinol Dose Escalation is Safe with Severe CKD

Save

Hypertension, nephrolithiasis and chronic kidney disease (CKD) commonly associates with gout.  While there is a clear need to dose adjust NSAIDs and colchicine in those with CKD, there is some debate about the need to dose adjust when using allopurinol with CKD.

Risk of Gout Onset and Flare Linked to Urate Levels

Save

Serum uric acid (SUA) levels are clearly linked to gout. Researchers from Harvard have systemically reviewed the literature to quantify the risk of onset and flare with varying levels of SUA.

Cannibis Weakly Effective in Neuropathic Pain

Save

The medical use of cannabis is often extended to management of chronic pain and neuropathic pain.

A metanalysis of 27 chronic pain trials show that there is low-strength evidence that cannabis alleviates neuropathic pain but insufficient evidence in other pain populations.

Cardiac Disturbances Increased in Spondyloarthritis

Save

A prospective Swedish study between 2001–2009 found a higher risk of aortic regurgitation, pacemaker, AV block and atrial fibrillation in SpA, AS, uSpA and PsA patients.

Registry Efficacy of Rituximab in Refractory SLE

Save

Despite large randomized trials failing to show the efficacy of RTX in SLE (LUNAR, EXPLORER), uncontrolled observational data suggests possible efficacy and safety of RTX in refractory SLE.

Frequency of Rheumatoid Knee Replacements Down in the Biologic Era

Save

A time-series analysis of incident rheumatoid arthritis (RA) patients seen between 1996 and 2011 in the Danish National Patient Register shows that the incidence of hip (THR) and knee replacements (TKR) began to decrease after the introdution of biologic agents for RA in 2002.

Baseline Risk Score Predicts Serious Infection Risk in TNF-Treated RA Patients

Save

Curtis and colleagues have analyzed the certolizumab (CZP) RAPID1 and RAPID2 trials to assess the risk of serious infectious events (SIEs), and shown that steroids combined with an age-adjusted comorbidity index (AACI) yields a 2-3 fold predictable risk for SIE.

Advantages of Intravenous Pulse Cyclophosphamide in ANCA-associated Vasculitis

Save

Researchers from the Nottingham University Hospitals have analyzed the efficacy and safety of  oral (PO) and intravenous (IV)  cyclophosphamide (CTX) in ANCA-associated vasculitis (AAV) patients and demonstrated a trend for fewer relapses, better 1 year survival and less toxicity w

The RheumNow Week in Review - 15 December 2017

Save

Dr. Jack Cush reviews the news from the past week on RheumNow.com. Subscribe to the podcast on iTunes and SoundCloud.com. 

FDA Approves Xeljanz for Use in Psoriatic Arthritis

Save

Pfizer Inc.